Dental Tribune U.S. Edition No. 10, 2016

Dental Tribune U.S. Edition | October 2016 a11 INDUSTRY NEWS AD Glidewell Laboratories launches Newport Biologics line of regenerative materials By Glidewell Laboratories Staff Glidewell Laboratories, an industry- leading provider of dental laboratory services and intraoral medical devices, has announced availability of a new line of bone grafting products, to be sold un- der the Newport Biologics™ brand name. Featuring allograft and alloplast bone graft options, as well as resorbable barrier membranes and a collagen-based wound dressing, the product line is aimed at in- creasing clinician access to top-quality re- generative materials for cases marked by bone or soft-tissue deficiencies. “The Newport Biologics line of bone grafting materials and resorbable bar- rier membranes represents the highest quality of regenerative products avail- able,” said Dr. Neil Park, director of clini- cal affairs for Glidewell Laboratories. “By assembling only the most versatile, effec- tive and frequently used regenerative ma- terials the industry has to offer, we hope to provide clinicians a simplified buying experience, unparalleled value and the confidence to efficiently and reliably treat the majority of grafting indications.” device manufacturer based in Newport Beach, Calif. Since inception, Glidewell has been driven by clinician demand and fueled by a mission to improve affordabil- ity of advanced dental procedures. The company advances the leading edge of dentistry, employing a diverse team of dentists, scientists, material researchers and other experienced professionals to develop products. For more information about the com- pany’s history and offerings, you can visit www.glidewelldental.com. To learn more about Newport Biologics, you can call (888) 303-3975 or visit www. newportbiologics.com. Along with the damaging cycle of tooth loss and tissue resorption known to result from periodontal defects, ex- traction sockets and other bone defi- ciencies, industry trends suggest that an increasing percentage of dental implant procedures require bone grafting to op- timize the esthetic and functional result. These and other factors have led to a dis- cernible rise in the demand for grafting procedures in the modern dental practice. “Unfortunately, there tends to be a lot of confusion in the marketplace,” Park said. “Different materials, of varying ori- gin and composition — all with propri- etary naming conventions — can make it difficult for dentists to determine which products are best suited for their patients’ needs.” Newport Biologics products are care- fully selected for the dental practice and processed in accordance with rigorous U.S. FDA regulations. The allograft mate- rials are sourced from the venerable Uni- versity of Miami Tissue Bank, the oldest in the nation, and resorbable membranes are engineered to optimize handling characteristics to support the clinician’s preferred bone-grafting techniques. In- dividual product names are intended to clearly reflect the material’s composition and usage. “We are very excited to add the Newport Biologics line to our growing portfolio of dental implant and restorative products,” said Dave Casper, president of Prismatik Dentalcraft, the manufacturing division of Glidewell Laboratories. “We’ve solicited feedback from some of the top opinion leaders in implant dentistry to bring a fo- cused line of regenerative products to our customers that can meet their bone graft- ing needs.” Founded in 1970, Glidewell Laborato- ries is a full-service dental lab and dental Glidewell Laboratories’ Newport Biologics product line increases clinicians’ access to regenerative materials for cases marked by bone or soft-tissue deficiencies. Photo/Provided by Glidewell Laboratories ADA BOOTH NO. 837

Dental Tribune U.S. Edition No. 10, 2016

Pages Overview